CONMED (CNMD)
(Delayed Data from NYSE)
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.59 USD
+0.03 (0.05%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $66.56 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up
by Zacks Equity Research
IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.
Orthofix's (OFIX) Q1 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.
CONMED (CNMD) Surges 4.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
CONMED (CNMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1
by Zacks Equity Research
CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.
Conmed (CNMD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 46.51% and 7.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Conmed (CNMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor optimism is high on CONMED (CNMD) stock, courtesy of its solid prospects.
CONMED (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Despite weak segmental performance in fourth quarter, CONMED (CNMD) showed strength and resilience in amid a tough operating environment.
Conmed (CNMD) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 7.69% and -3.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MCK or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MCK vs. CNMD: Which Stock Is the Better Value Option?
LH or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
LH or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
LH vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3
Conmed (CNMD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 252.00% and 16.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Conmed (CNMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Avoid Betting on Integer Holdings Now
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational performance weighs on Integer Holdings (ITGR).
Cerner Inks Deal to Simplify Advance Care Planning Procedure
by Zacks Equity Research
Cerner's (CERN) partners with Vynca to simplify advance care planning process, thereby enabling patients and clinicians to discuss and make critical end-of-life decisions.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top
by Zacks Equity Research
CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.
Conmed (CNMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 93.14% and 22.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy CONMED (CNMD) Ahead of Earnings?
by Zacks Equity Research
CONMED (CNMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Conmed (CNMD) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.